Published in Clin Infect Dis on August 16, 2005
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 6.61
Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev (2009) 5.76
Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis (2011) 4.09
Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis (2007) 3.73
Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol (2007) 3.51
Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group. Antimicrob Agents Chemother (2008) 3.24
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother (2009) 2.12
Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care (2006) 2.07
The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol (2009) 2.06
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother (2008) 2.03
Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. J Bacteriol (2008) 2.02
The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci (2009) 1.94
Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother (2006) 1.94
Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2007) 1.81
Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun (2007) 1.77
Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc Natl Acad Sci U S A (2011) 1.72
Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii. J Clin Microbiol (2009) 1.71
Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence (2012) 1.63
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun (2010) 1.61
Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of bla(OXA-51-like) genes. J Clin Microbiol (2010) 1.59
Gram-negative antibiotic resistance: there is a price to pay. Crit Care (2008) 1.58
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res (2010) 1.52
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother (2011) 1.50
X-box binding protein 1 (XBP1s) is a critical determinant of Pseudomonas aeruginosa homoserine lactone-mediated apoptosis. PLoS Pathog (2013) 1.50
Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog (2012) 1.47
Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol (2010) 1.47
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.43
Hospital acquired antibiotic-resistant acinetobacter baumannii infections in a 400-bed hospital in Tehran, Iran. Int J Prev Med (2011) 1.36
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother (2012) 1.35
Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect (2011) 1.33
Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control (2009) 1.27
Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother (2009) 1.27
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.26
Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun (2010) 1.24
Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother (2006) 1.23
Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol (2007) 1.23
Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica (2010) 1.23
The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis (2009) 1.21
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother (2008) 1.21
Acinetobacter septicus sp. nov. association with a nosocomial outbreak of bacteremia in a neonatal intensive care unit. J Clin Microbiol (2007) 1.20
Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control (2014) 1.20
Discovery of 1,4-dihydroxy-2-naphthoate [corrected] prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens. J Med Chem (2007) 1.19
VIM-1 metallo-beta-lactamase in Acinetobacter baumannii. Emerg Infect Dis (2006) 1.18
Genomic analysis of Acinetobacter baumannii A118 by comparison of optical maps: identification of structures related to its susceptibility phenotype. Antimicrob Agents Chemother (2011) 1.16
Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.16
Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect Immun (2008) 1.15
Epidemiology and Ecology of Opportunistic Premise Plumbing Pathogens: Legionella pneumophila, Mycobacterium avium, and Pseudomonas aeruginosa. Environ Health Perspect (2015) 1.14
Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect Immun (2011) 1.14
In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother (2008) 1.14
Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One (2012) 1.12
Identification of Gram-Negative Bacteria and Genetic Resistance Determinants from Positive Blood Culture Broths by Use of the Verigene Gram-Negative Blood Culture Multiplex Microarray-Based Molecular Assay. J Clin Microbiol (2015) 1.12
Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase. Protein Sci (2011) 1.12
Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis (2008) 1.10
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides. Antimicrob Agents Chemother (2009) 1.10
Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther (2008) 1.09
Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol (2009) 1.07
Surface-localized spermidine protects the Pseudomonas aeruginosa outer membrane from antibiotic treatment and oxidative stress. J Bacteriol (2011) 1.07
Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother (2007) 1.06
The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun (2013) 1.06
Antibiotic resistance and expression of resistance-nodulation-division pump- and outer membrane porin-encoding genes in Acinetobacter species isolated from Canadian hospitals. Can J Infect Dis Med Microbiol (2013) 1.05
Role of the lysozyme inhibitor Ivy in growth or survival of Escherichia coli and Pseudomonas aeruginosa bacteria in hen egg white and in human saliva and breast milk. Appl Environ Microbiol (2008) 1.05
Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun (2008) 1.04
Research on the treatment of Pseudomonas aeruginosa pneumonia in children by macrolide antibiotics. Open Med (Wars) (2015) 1.04
Environmental contamination because of multidrug-resistant Acinetobacter baumannii surrounding colonized or infected patients. Am J Infect Control (2011) 1.03
Multicenter evaluation of a new shortened peptide nucleic acid fluorescence in situ hybridization procedure for species identification of select Gram-negative bacilli from blood cultures. J Clin Microbiol (2010) 1.03
Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands. Antimicrob Agents Chemother (2013) 1.02
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother (2013) 1.01
Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis (2014) 1.00
Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit. J Clin Microbiol (2007) 1.00
Widespread Emergence of Multidrug Resistant Pseudomonas aeruginosa Isolated from CSF Samples. Indian J Microbiol (2011) 0.99
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist (2013) 0.99
Acinetobacter pneumonia: a review. MedGenMed (2007) 0.99
genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii. Infect Immun (2012) 0.98
In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother (2011) 0.98
Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect (2007) 0.98
Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. Pharmaceuticals (Basel) (2013) 0.98
Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond. J Bacteriol (2015) 0.97
Changes in urine composition after trauma facilitate bacterial growth. BMC Infect Dis (2012) 0.97
Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes. J Antimicrob Chemother (2008) 0.97
Spreading of AbaR-type genomic islands in multidrug resistance Acinetobacter baumannii strains belonging to different clonal complexes. Curr Microbiol (2013) 0.96
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2008) 0.96
Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey. Infect Control Hosp Epidemiol (2012) 0.96
Structural Relationship of the Lipid A Acyl Groups to Activation of Murine Toll-Like Receptor 4 by Lipopolysaccharides from Pathogenic Strains of Burkholderia mallei, Acinetobacter baumannii, and Pseudomonas aeruginosa. Front Immunol (2015) 0.96
Current Concepts and Ongoing Research in the Prevention and Treatment of Open Fracture Infections. Adv Wound Care (New Rochelle) (2015) 0.95
Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar. Ann Clin Microbiol Antimicrob (2010) 0.94
A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother (2013) 0.94
Stress responses in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol (2013) 0.93
Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymycins. J Org Chem (2012) 0.93
Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. Diagn Microbiol Infect Dis (2013) 0.93
Serratamolide is a hemolytic factor produced by Serratia marcescens. PLoS One (2012) 0.92
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2007) 0.92
dATP/ATP, a multifunctional nucleotide, stimulates bacterial cell lysis, extracellular DNA release and biofilm development. PLoS One (2010) 0.91
Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam Med J (2014) 0.91
Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: Clinical characteristics and outcome. Indian J Crit Care Med (2013) 0.91
Type IV pili interactions promote intercellular association and moderate swarming of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2014) 0.91
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control (2004) 14.85
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol (2008) 13.49
Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep (2007) 11.94
Multistate point-prevalence survey of health care-associated infections. N Engl J Med (2014) 8.78
Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol (2012) 6.27
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis (2004) 5.67
Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis (2005) 4.52
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA (2009) 3.06
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control (2002) 2.49
National Healthcare Safety Network (NHSN) Report, data summary for 2010, device-associated module. Am J Infect Control (2011) 2.12
Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics (2006) 1.91
National Healthcare Safety Network (NHSN) report, data summary for 2012, Device-associated module. Am J Infect Control (2013) 1.70
National estimates of central line-associated bloodstream infections in critical care patients. Infect Control Hosp Epidemiol (2013) 1.69
Effect of nurse staffing and antimicrobial-impregnated central venous catheters on the risk for bloodstream infections in intensive care units. Infect Control Hosp Epidemiol (2003) 1.69
Dialysis Surveillance Report: National Healthcare Safety Network (NHSN)-data summary for 2006. Semin Dial (2008) 1.67
Improving risk-adjusted measures of surgical site infection for the national healthcare safety network. Infect Control Hosp Epidemiol (2011) 1.66
Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics (2012) 1.66
The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis (2008) 1.64
National Healthcare Safety Network report, data summary for 2011, device-associated module. Am J Infect Control (2013) 1.63
Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis (2002) 1.40
National Healthcare Safety Network (NHSN) report, data summary for 2009, device-associated module. Am J Infect Control (2011) 1.38
Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus infection in neonatal intensive care units: data from the National Nosocomial Infections Surveillance System, 1995-2004. Pediatr Infect Dis J (2009) 1.16
Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990-2010. Infect Control Hosp Epidemiol (2013) 1.11
Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis (2002) 1.10
Device-associated infections among neonatal intensive care unit patients: incidence and associated pathogens reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol (2012) 1.04
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis (2013) 1.03
Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990-2007. Infect Control Hosp Epidemiol (2011) 0.93
Improved risk adjustment in public reporting: coronary artery bypass graft surgical site infections. Infect Control Hosp Epidemiol (2012) 0.89
Incidence and Characteristics of Ventilator-Associated Events Reported to the National Healthcare Safety Network in 2014. Crit Care Med (2016) 0.89
Cough and cold medication adverse events after market withdrawal and labeling revision. Pediatrics (2013) 0.87
Incidence of pediatric and neonatal intensive care unit-acquired infections. Infect Control Hosp Epidemiol (2006) 0.85
Sampling for collection of central line-day denominators in surveillance of healthcare-associated bloodstream infections. Infect Control Hosp Epidemiol (2006) 0.83
Survey of health care-associated infections. N Engl J Med (2014) 0.81
Measurement of the impact of risk adjustment for central line-days on interpretation of central line-associated bloodstream infection rates. Infect Control Hosp Epidemiol (2007) 0.81
Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014. MMWR Morb Mortal Wkly Rep (2016) 0.81
Evaluating the accuracy of sampling to estimate central line-days: simplification of the National Healthcare Safety Network surveillance methods. Infect Control Hosp Epidemiol (2013) 0.78
Improving benchmarks for surveillance by defining types of pediatric intensive care units. Am J Infect Control (2002) 0.78
Device-associated infection rates, device utilization, and antimicrobial resistance in long-term acute care hospitals reporting to the National Healthcare Safety Network, 2010. Infect Control Hosp Epidemiol (2012) 0.76
Effect of carbon dioxide on broth microdilution susceptibility testing of Brucella spp. J Clin Microbiol (2009) 0.75